Now, what about mRNA vaccines?

The short version: mRNA vaccines reduce all-cause mortality in older adults but carry a real, dose-dependent myocarditis risk in young males that is not trivial.

The Norwegian cohort of 4.6 million people found that adults who got three or more mRNA doses had about 60% lower all-cause mortality than the unvaccinated over three years [1]. That is a large effect, but it comes from an observational study where the healthy-vaccinee bias is real: people who get multiple shots tend to be healthier to begin with. The authors acknowledge this [1]. The Danish heart-failure study found a smaller mortality benefit (2.2% vs 2.6% over 90 days) and no increase in worsening heart failure [2]. The Israeli long-term care study found the vaccine cut all-cause deaths by about 64% in the first month [3]. These are consistent signals that mRNA vaccines protect the most vulnerable.

The myocarditis risk is the other side. The BMJ living review found that in males 12-29 years, myocarditis occurs at 28-147 cases per million doses, mostly after the second dose, with Moderna probably riskier than Pfizer [10]. The meta-analysis of adolescents put the rate at about 16 per 100,000 in males after the second Pfizer dose [19]. Over half of those followed for three months still had echocardiogram abnormalities or ongoing symptoms [10]. The disease course is usually mild, but "mild" in a 16-year-old with a damaged heart is not nothing.

The US nursing-home study found that elevated mortality after infection persisted longer in the vaccinated (5 weeks) than the unvaccinated (1 week) [4]. That is a warning sign that repeated boosting may narrow immune response rather than broaden it. The county-level US study found a positive association between vaccine uptake and excess mortality in 2022-2023 [6]. These are ecological correlations, not proof of harm, but they are the kind of signal the system does not investigate.

My call: for adults over 50, the mortality benefit is real and the myocarditis risk is negligible. For males under 30, especially adolescents, the myocarditis risk is high enough that the decision requires individual calculation, not blanket recommendation. The evidence does not support mandates for young males. Confidence: moderate for benefit in older adults, moderate for myocarditis risk in young males, low for long-term harm signals.